Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
Open accessAbstract
Background Excess body-mass index (BMI) has been associated with adverse outcomes in prostate cancer, and hyperinsulinaemia is a candidate mediator, but prospective data are sparse. We assessed the effect of prediagnostic BMI and plasma C-peptide concentration (reflecting insulin secretion) on prostate cancer-specific mortality after diagnosis.Methods This study involved men diagnosed with prostate cancer during the 24 years of follow-up in the Physicians' Health Study. BMI measurements were available at baseline in 1982 and eight years later in 1990 for 2546 men who developed prostate cancer. Baseline C-peptide concentration was available in 827 men. We used Cox proportional hazards regression models controlling for age, smoking, time between BMI measurement and prostate cancer diagnosis, and competing causes of death to assess the risk of prostate cancer-specific mortality according to BMI and C-peptide concentration.Findings Of the 2546 men diagnosed with prostate cancer during the follow-up period, 989 (38.8%) were overweight (BMI 25.0-29.9 kg/m(2)) and 87 (3.4%) were obese (BMI >/=30 kg/m(2)). 281 men (11%) died from prostate cancer during this follow-up period. Compared with men of a healthy weight (BMI <25 kg/m(2)) at baseline, overweight men and obese men had a significantly higher risk of prostate cancer mortality (proportional hazard ratio [HR] 1.47 [95% CI 1.16-1.88] for overweight men and 2.66 [1.62-4.39] for obese men; p(trend)<0.0001). The trend remained significant after controlling for clinical stage and Gleason grade and was stronger for prostate cancer diagnosed during the PSA screening era (1991-2007) compared with during the pre-PSA screening era (1982-1990) or when using BMI measurements obtained in 1990 compared with those obtained in 1982. Of the 827 men with data available for baseline C-peptide concentration, 117 (14%) died from prostate cancer. Men with C-peptide concentrations in the highest quartile (high) versus the lowest quartile (low) had a higher risk of prostate cancer mortality (HR 2.38 [95% CI 1.31-4.30]; p(trend)=0.008). Compared with men with a BMI less than 25 kg/m(2) and low C-peptide concentrations, those with a BMI of 25 kg/m(2) or more and high C-peptide concentrations had a four-times higher risk of mortality (4.12 [1.97-8.61]; p(interaction)=0.001) independent of clinical predictors.Interpretation Excess bodyweight and a high plasma concentration of C-peptide both predispose men with a subsequent diagnosis of prostate cancer to an increased likelihood of dying of their disease. Patients with both factors have the worst outcome. Further studies are now needed to confirm these findings.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Obesity has not been associated, and in some studies is even inversely associated, with prostate cancer incidence.
“While obesity has not been associated, and in some studies is even inversely associated, with prostate cancer incidence”
From Diabetes and Cancer (2010) · cites this paper as [7]
Obese men with prostate cancer have higher cancer mortality rates than normal weight men.
“obese men with prostate cancer have higher cancer mortality rates than those of normal weight (7).”
From Diabetes and Cancer (2010) · cites this paper as [7]
Higher pre-diagnosis C-peptide levels have been associated with a poorer disease-specific survival for prostate cancer and colorectal cancer.
“higher pre-diagnosis C-peptide levels (an indirect marker of insulin resistance) have been associated with a poorer disease-specific survival for prostate cancer (7) and colorectal cancer (10).”
From Diabetes and Cancer (2010) · cites this paper as [7]
Obesity may also increase risk of mortality from some cancers, such as prostate.
“Obesity may also increase risk of mortality from some cancers, such as prostate (7).”
From Diabetes and Cancer (2010) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Statistical Models Based on Counting Processes
Bry, X., Andersen, P. K., Borgan, Ø., Gill, R. D., Keiding, N., & Borgan, Ø. (1997) · Population · doi:10.2307/1534625 · Cited by 2,884 · see citing works
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,269 · see citing works
Tumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,125 · see citing works
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · see citing works
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455 · see citing works
Giovannucci, E. L., Liu, Y., Platz, E. A., Stampfer, M. J., & Willett, W. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22788 · Cited by 513 · see citing works
Self-citationStatistical Models Based on Counting Processes.
Crowley, J. J., Liu, P., Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1994) · Journal of the American Statistical Association · doi:10.2307/2291236 · Cited by 485 · see citing works
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., PEZZINO, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 408 · see citing works
Body size and composition and prostate cancer risk: systematic review and meta-regression analysis
MacInnis, R. J., & English, D. R. (2006) · Cancer Causes & Control · doi:10.1007/s10552-006-0049-z · Cited by 406 · see citing works
Basaria, S. S., Muller, D. C., Carducci, M. A., Egan, J. M., & Dobs, A. S. (2005) · Cancer · doi:10.1002/cncr.21642 · Cited by 388 · see citing works
Amling, C. L., Riffenburgh, R. H., Sun, L. L., Moul, J. W., Lance, R. S., Kusuda, L., Sexton, W. J., Soderdahl, D. W., Donahue, T. F., Foley, J. P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.132 · Cited by 384 · see citing works
Freedland, S. J., Aronson, W. J., Kane, C. J., Presti, J. C., Amling, C. L., Elashoff, D. A., & Terris, M. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.181 · Cited by 382 · see citing works
Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer
Bañez, L. L., Hamilton, R. J., Partin, A. W., Vollmer, R. T., Sun, L. L., Rodríguez, C., Wang, Y., Terris, M. K., Aronson, W. J., Presti, J. C., et al. (2007) · JAMA · doi:10.1001/jama.298.19.2275 · Cited by 357 · see citing works
Rodríguez, C., Freedland, S. J., Deka, A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Thun, M. J., & Calle, E. E. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0754 · Cited by 354 · see citing works
Wright, M. E., Chang, S., Schatzkin, A. G., Albanes, D., Kipnis, V., Mouw, T., Hurwitz, P. E., Hollenbeck, A. R., & Leitzmann, M. F. (2007) · Cancer · doi:10.1002/cncr.22443 · Cited by 336 · see citing works
A Prospective Study of Plasma C-Peptide and Colorectal Cancer Risk in Men
Ma, J., Giovannucci, E. L., Pollak, M., Leavitt, A., Tao, Y., Gaziano, J. M., & Stampfer, M. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh082 · Cited by 330 · see citing works
Self-citationProstate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study
Hsing, A. W., Chua, S. C., Gao, Y., Gentzschein, E., Chang, L. J., Deng, J., & Stanczyk, F. Z. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.783 · Cited by 295 · see citing works
Insulin receptor expression by human prostate cancers
Cox, M., Gleave, M. E., Zakikhani, M., Bell, R. H., Piura, E., Vickers, E., Cunningham, M., Larsson, O. S., Fazli, L., & Pollak, M. (2008) · The Prostate · doi:10.1002/pros.20852 · Cited by 221 · see citing works
Self-citationHyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer
Hammarsten, J., & Högstedt, B. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.003 · Cited by 215 · see citing works
Venkateswaran, V. K., Haddad, A., Fleshner, N. E., Fan, R., Sugar, L., Nam, R. K., Klotz, L. H., & Pollak, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm231 · Cited by 182 · see citing works
Self-citationGong, Z., Agalliu, I., Lin, D. W., Stanford, J. L., & Kristal, A. R. (2007) · Cancer · doi:10.1002/cncr.22534 · Cited by 158 · see citing works
Prediction of Cumulative Incidence Function under the Proportional Hazards Model
Cheng, S. C., Fine, J. P., & Wei, L. J. (1998) · Biometrics · doi:10.2307/2534009 · Cited by 156 · see citing works
Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE
Bassett, W. W., Cooperberg, M. R., Sadetsky, N., et al. (2005) · Urology · doi:10.1016/j.urology.2005.05.040 · Cited by 141 · see citing works
Trends in Hyperinsulinemia Among Nondiabetic Adults in the U.S.
Li, C., Ford, E. S., McGuire, L. C., Mokdad, A. H., Little, R. R., & Reaven, G. M. (2006) · Diabetes Care · doi:10.2337/dc06-0289 · Cited by 136 · see citing works
Strom, S. S., Wang, X., Pettaway, C. A., Logothetis, C. J., Yamamura, Y., Do, K.-A., Babaian, R. J., & Troncoso, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1977 · Cited by 134 · see citing works
Obesity and survival after radical prostatectomy: A 10‐year prospective cohort study
Siddiqui, S. A., Inman, B. A., Sengupta, S., Slezak, J. M., Bergstralh, E. J., Leibovich, B. C., Zincke, H., & Blute, M. L. (2006) · Cancer · doi:10.1002/cncr.22030 · Cited by 118 · see citing works
Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden
Stocks, T., Lukanova, A., Rinaldi, S., Biessy, C., Dossus, L., Lindahl, B., Hallmans, G., Kaaks, R., & Stattin, P. E. (2007) · International Journal of Cancer · doi:10.1002/ijc.22587 · Cited by 109 · see citing works
Strom, S. S., Kamat, A. M., Gruschkus, S. K., et al. (2006) · Cancer · doi:10.1002/cncr.22025 · Cited by 104 · see citing works
Standardization of C-peptide measurements
Little, R. R., Rohlfing, C. L., Tennill, A. L., Madsen, R. W., Polonsky, K. S., Myers, G. L., Greenbaum, C. J., Palmer, J. P., Rogatsky, E., & Stein, D. T. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101287 · Cited by 103 · see citing works
Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict?
Freedland, S. J., Giovannucci, E. L., & Platz, E. A. (2006) · Cancer Causes & Control · doi:10.1007/s10552-005-0378-3 · Cited by 100 · see citing works
Self-citationObesity and mortality in men with locally advanced prostate cancer
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2007) · Cancer · doi:10.1002/cncr.23093 · Cited by 99 · see citing works
Chen, C., Lewis, S. K., Voigt, L. F., et al. (2004) · Cancer · doi:10.1002/cncr.20727 · Cited by 92 · see citing works
Anthropometrics and Prostate Cancer Risk
Littman, A. J., White, E., & Kristal, A. R. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm013 · Cited by 77 · see citing works
Stroup, S. P., Cullen, J. C., Auge, B. K., L’Esperance, J. O., & Kang, S. K. (2007) · Cancer · doi:10.1002/cncr.22873 · Cited by 65 · see citing works
Mallah, K. N., DiBlasio, C. J., Rhee, A. C., Scardino, P. T., & Kattan, M. W. (2005) · Cancer · doi:10.1002/cncr.20991 · Cited by 63 · see citing works
Palma, D. A., Pickles, T., Tyldesley, S. K., et al. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06897.x · Cited by 53 · see citing works
Lehrer, S., Diamond, E. J., Stagger, S., Stone, N. N., & Stock, R. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600526 · Cited by 48 · see citing works
Gallina, A., Karakiewicz, P. I., Hutterer, G. C., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22730 · Cited by 47 · see citing works
Obesity Is Not Predictive of Overall Survival Following Permanent Prostate Brachytherapy
Merrick, G. S., Galbreath, R. W., Butler, W. M., Wallner, K. E., Allen, Z. A., & Adamovich, E. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318068b506 · Cited by 30 · see citing works
Chun, F. K. ‐., Briganti, A., Graefen, M., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.037 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · see citing works
Self-citationInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · see citing works
Self-citationNutrition and physical activity guidelines for cancer survivors
Rock, C. L., Doyle, C., Demark‐Wahnefried, W., Meyerhardt, J., Courneya, K. S., Schwartz, A. L., Bandera, E. V., Hamilton, K. K., Grant, B., McCullough, M., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21142 · Cited by 1,995 · see citing works
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009 · see citing works
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806 · see citing works
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · see citing works
Kenfield, S. A., Stampfer, M. J., Giovannucci, E., & Chan, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5226 · Cited by 601 · see citing works
Self-citationPetrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530 · see citing works
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0329-9 · Cited by 288 · see citing works
Wright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276 · see citing works
Insulin resistance and cancer: The role of insulin and IGFs
Djiogue, S., Nwabo Kamdje, A. H., Vecchio, L., Kipanyula, M. J., Farahna, M., Aldebasi, Y., & Seke Etet, P. F. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0324 · Cited by 263 · see citing works
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Cooper, R. S. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq341 · Cited by 223 · see citing works
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0615 · Cited by 202 · see citing works
Cai, H., Xu, Z., Xu, T., Yu, B., & Zou, Q. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2582 · Cited by 80 · see citing works
- Authors
- Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., Gaziano, J. M., Pollak, M., & Stampfer, M. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Corresponding author
- Ma, Jing
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 9
- Issue
- 11
- Pages
- 1039-1047
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC2651222
- OpenAlex
- W2099777151
- Cited by
- 421
- References
- 40
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 14 · 2023: 13 · 2022: 10 · 2021: 15 · 2020: 23 · 2019: 14 · 2018: 23 · 2017: 32 · 2016: 34 · 2015: 34 · 2014: 38 · 2013: 31 · 2012: 28
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01 HL026490, R01HL034595)
- National Cancer Institute (R01CA040360, R01CA042182, CA 42182, R01 CA034944, R01CA058684, CA90598, R01CA097193, CA 40360, R01CA090598, CA-58684, R29CA078293)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK040561)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Keywords
- prostate cancer, body mass index, obesity, overweight, C-peptide, hyperinsulinemia, insulin secretion, prostate cancer-specific mortality, PSA screening, long-term survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, C-Peptide, Follow-Up Studies, Humans, Hyperinsulinism, Male, Middle Aged, Obesity, Physicians, Prostatic Neoplasms, Risk Factors, United States, Biomarkers, Body Mass Index, Multivariate Analysis, Proportional Hazards Models, Case-Control Studies, Prostate-Specific Antigen, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
